Comparing Insulet (NASDAQ:PODD) and BZAM (OTCMKTS:BZAMF)

Insulet (NASDAQ:PODD) and BZAM (OTCMKTS:BZAMF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Insulet and BZAM, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	0	2	21	1	2.96
BZAM	0	0	0	0	0.00

Insulet currently has a consensus target price of $381.75, indicating a potential upside of 29.69%. Given Insulet’s stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than BZAM.

Profitability

This table compares Insulet and BZAM’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insulet	9.76%	24.36%	10.02%
BZAM	N/A	N/A	N/A

Earnings and Valuation

This table compares Insulet and BZAM”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.07 billion	10.00	$418.30 million	$3.45	85.32
BZAM	N/A	N/A	N/A	($0.27)	N/A

Insulet has higher revenue and earnings than BZAM. BZAM is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.0% of BZAM shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 8.7% of BZAM shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Insulet beats BZAM on 9 of the 11 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

About BZAM

BZAM Ltd. operates as a cannabis producer with a focus on branded consumer goods. Its brands include the BZAM, TGOD, ness, Highly Dutch Organic, and TABLE TOP, as well as Dunn Cannabis, FRESH, and Wyld partner brands. The company operate facilities in British Columbia, Alberta, Ontario, and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan. The company was formerly known as The Green Organic Dutchman Holdings Ltd. and changed its name to BZAM Ltd. in February 2023. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.